SEC Ponzi actions, FDA dual approvals, and FTC $12M processor ban — September 8–14, 2026

The September 8–14, 2026 window produced eight significant regulatory actions across the SEC, FDA, and FTC: four SEC enforcement matters, three FDA actions spanning therapeutic approvals and food safety, and one FTC enforcement settlement alongside active calendar deadlines. The primary compliance task is to separate filed complaints from entered consent judgments, update oncology and neuromuscular clinical formularies, test high-risk payment processor onboarding controls, and mark three fixed dates in the regulatory calendar.

On September 10, 2026, the SEC filed an enforcement action in the Eastern District of New York charging Ernest Ossei Boateng and his controlled entities, Intercontinental Wealth Network LLC and I Wealth Network LP. 1 The complaint alleges that from January 2020 to March 2026, Boateng raised roughly $16 million from more than 200 investors by promising fixed returns generated through conservative investment strategies. The SEC states that the offering targeted Ghanaian Christians in New York and New Jersey, assuring them that their capital had insurance protection against losses. 9

According to the complaint, Boateng misappropriated more than $5.8 million for personal expenses, including buying and furnishing a home, and redirected $6.6 million to pay earlier investors. The remaining capital was deployed in speculative day trading that generated over $750,000 in trading losses. The SEC charges Boateng, Intercontinental, and I Wealth with antifraud violations under Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act, and Section 206 of the Investment Advisers Act. The Commission seeks permanent injunctions, conduct-based bans, disgorgement with interest, and civil monetary penalties. Registered investment advisers and private fund managers should inspect investor solicitation materials, confirm that marketing claims match underlying investment mandates, and audit cash movement controls between fund accounts and executive entities.

On September 8, 2026, the SEC announced settled charges against Francisco Javier Sarabia, the president and co-founder of Bonanza Global Solutions LLC. 2 The SEC complaint, filed in the Central District of California, alleges that Sarabia raised over $5 million from more than 350 Spanish-speaking and Filipino investors between February 2022 and March 2023. 10 Sarabia represented that Bonanza Global was a legitimate hedge fund generating 10% to 15% monthly returns through equities trading, backed by a principal guarantee.

The SEC found that Bonanza Global generated zero operational revenue. Investor deposits were used to fund luxury goods, travel, and Ponzi-style distributions to prior participants. Without admitting or denying the allegations, Sarabia consented to a final judgment imposing permanent injunctions under Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act, and Sections 5(a) and 5(c) registration rules. The settlement subjects Sarabia to a permanent conduct-based injunction barring him from participating in securities offerings, alongside $825,000 in disgorgement and $215,137 in prejudgment interest. The immediate next action is formal entry of the judgment by the district court. Fund compliance teams should treat promised double-digit monthly guarantees as an automatic disqualifier during third-party fund manager due diligence.

On September 8, 2026, the Eastern District of New York entered a final consent judgment against Justin Chen, resolving SEC litigation filed in August 2025. 3 Chen worked for a financial printing and filing service that prepared public filings for transmission through the SEC's EDGAR system. The SEC established that Chen and a colleague extracted material nonpublic information regarding upcoming merger announcements and corporate earnings reports, executing trades across 13 separate corporate events to capture more than $2.2 million in unlawful profits. 11

The final judgment imposes permanent antifraud injunctions under Sections 10(b) and 14(e) of the Exchange Act and finds Chen liable for $1,828,442 in disgorgement plus $32,361 in prejudgment interest. The court ordered that his monetary obligation is satisfied by restitution and forfeiture orders entered in his parallel criminal prosecution, United States v. Chen. The SEC noted that the investigation used Consolidated Audit Trail trade matching data to pinpoint the irregular pre-announcement positioning. Filing agents, legal printers, and corporate secretaries should audit digital file rooms, restrict pre-filing document access to named working groups, and run access log reconciliations against personal trading declarations.

On September 10, 2026, the SEC charged Adam B. Rundle in the District of Maryland with running an offering scheme that raised approximately $1.5 million. 4 The complaint alleges that between November 2021 and January 2024, Rundle assumed the identity of a licensed securities broker to persuade an investor to purchase a Simple Agreement for Future Equity issued by Robinvest LLC, an entity Rundle owned and operated. 12

Rundle falsely claimed the SAFE carried guaranteed principal protection and a 4% annual compounded return. The SEC alleges that Rundle diverted all investor capital into personal accounts, converted the funds into cryptocurrency, and lost the entire amount through trading. The complaint charges Rundle with violations of Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act, seeking permanent injunctive relief, civil penalties, and full disgorgement. Angel syndicates, venture investors, and early-stage issuers should independently confirm broker and intermediary registrations through FINRA BrokerCheck before wiring funds for private instruments.

On September 9, 2026, the FDA granted expanded accelerated approval to Bayer's sevabertinib (marketed as Hyrnuo), an oral tyrosine kinase inhibitor. 5 The expanded label covers adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors harbor HER2 (ERBB2) tyrosine kinase domain activating mutations, as confirmed by an FDA-authorized diagnostic test. This regulatory decision broadens sevabertinib's prior accelerated indication, allowing administration in treatment-naive patients.

The regulatory determination rested on cohort data from the open-label, multicenter SOHO-01 clinical trial (NCT05099172). In 69 treatment-naive patients with HER2 TKD activating mutations, sevabertinib delivered a confirmed objective response rate of 75% under blinded independent central review, with 73% of responders maintaining responses for six months or longer and 38% maintaining responses for at least 12 months. The recommended dose is 20 mg orally twice daily with food. The prescribing information outlines warnings and precautions for diarrhea, hepatotoxicity, interstitial lung disease, left ventricular dysfunction, ocular toxicity, elevated pancreatic enzymes, and embryo-fetal harm. The review was completed under Project Orbis in coordination with the United Kingdom's Medicines and Healthcare products Regulatory Agency. Oncology networks and hospital formularies must establish verified companion diagnostic workflows before prescribing.

On September 11, 2026, the FDA approved Scholar Rock's Isembyld (apitegromab-mstn) injection for adults and pediatric patients aged two years and older with spinal muscular atrophy who are actively receiving an SMN2-directed therapy. 6 Isembyld represents the first regulatory clearance for a therapy specifically engineered to counteract muscle loss in SMA, functioning as an add-on treatment to existing survival motor neuron therapies.

The approval follows the 52-week double-blind, placebo-controlled SAPPHIRE trial (NCT05156320) in 188 non-ambulatory SMA patients aged two to 21 years. The primary efficacy cohort of 156 patients aged two to 12 years demonstrated statistically significant motor improvement on the Hammersmith Functional Motor Scale Expanded at 52 weeks, with 34.2% of treated patients achieving clinically meaningful functional gains compared with 13.5% in the placebo group. The safety profile highlights an elevated incidence of bone fractures alongside common adverse events including upper respiratory tract infections, vomiting, cough, viral illnesses, headache, gastroenteritis, and pharyngitis. Specialty pharmacies, pediatric neurologists, and health plans must incorporate bone health assessments and concurrent SMN2 medication verification into prior authorization workflows.

On September 9, 2026, the FDA and CDC released an updated advisory regarding an active multistate outbreak of Salmonella Bovismorbificans tied to broccoli sprouts produced by Evergreen Fresh Sprouts LLC of Moyie Springs, Idaho. 7 The epidemiological investigation counts 22 confirmed illnesses across Idaho, Montana, Utah, and Washington, resulting in two hospitalizations. Illness onsets ranged from July 7 through August 26, 2026.

Evergreen Fresh Sprouts initiated a voluntary product recall on September 4, 2026, after Montana state agricultural officials detected Salmonella in a retail broccoli sprouts sample. Whole genome sequencing matched the sample isolate to the clinical outbreak strain. The recalled items carry expiration dates of September 7, September 9, September 11, September 14, and September 16, 2026, distributed in plastic clamshells and bags to grocers, food service providers, and restaurants. Retail food establishments, wholesalers, and commercial kitchens must confirm that affected lots have been quarantined and destroyed, and sanitize storage equipment that came into direct contact with the inventory.

On September 8, 2026, the FTC announced a civil enforcement action and proposed stipulated order in the Eastern District of Michigan against 5967 Ventures LLC, doing business as Humboldt Merchant Services. 8 The FTC alleges that Humboldt knowingly facilitated credit card payment processing for more than 1,000 sham merchant entities engaged in deceptive billing scams and unauthorized charges between 2021 and 2023, generating over $100 million in fraudulent transaction volume. 13

The FTC's complaint shows that Humboldt catered to high-risk performance marketing and online nutraceutical sellers that generated chargeback rates exceeding 7%, vastly above card network monitoring thresholds. To circumvent credit card network scrutiny and prevent transaction denials, Humboldt shifted sham accounts to a lower-risk bank identification number belonging to an affiliated entity. The proposed settlement requires Humboldt to pay $12 million for consumer redress and imposes permanent structural prohibitions. Humboldt is barred from payment processing for straw companies, merchants on Mastercard's MATCH list for fraud or laundering, entities subject to law enforcement actions, and e-commerce merchants whose sole physical location is a commercial mailbox provider. The order also enjoins Humboldt from assisting clients with load balancing or falsifying merchant applications. Acquirers, independent sales organizations, and fintech platforms should immediately audit portfolio underwriting, re-screen high-risk merchant physical addresses, and test chargeback monitoring controls.

Procedural actions in the Chen and Sarabia matters depend on district court order entry, while the Boateng and Rundle cases will advance through answer deadlines and discovery scheduling in their respective federal courts. The sevabertinib approval obligates Bayer to complete post-marketing confirmatory studies to verify clinical benefit.

Primary agency documents published this week do not document verified causal equity price movements for the named corporate participants. Market participants should concentrate resources on testing onboarding screens for payment intermediaries, updating molecular oncology panels, and maintaining scheduled comment workflows for pending agency policy initiatives.